5 completed, 5 terminated, 1 unknown, 1 withdrawn. 12 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 12 | Completed 5, Terminated 5, Unknown 1, Withdrawn 1 |
| Phase 1 | 1 | Completed 1 |
Follow brodalumab: new trials by email Literature Review of brodalumab trials Research Report on brodalumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Treatment of Moderate Hidradenitis Suppurativa Brodalumab - Hidradenitis Suppurativa | Phase 2 | Unknown | Florida Academic Dermatology Centers | 20 | 2019-05-01 | 2019-04-10 |
| Study of Efficacy and Safety of Brodalumab Compared With Placebo in Subjects With Axial Spondyloarthritis Brodalumab 210 mg, Placebo - Axial Spondyloarthritis | Phase 2 | Withdrawn | Amgen | 2015-05-01 | 2015-06-19 | |
| Study of Efficacy and Safety of Brodalumab Compared With Placebo in Adults With Inadequately Controlled Asthma With High Bronchodilator Reversibility Placebo, Brodalumab - Asthma | Phase 2 | Terminated | Amgen | 421 | 2013-05-22 | 2022-09-21 |
| A Phase 2 Clinical Study of KHK4827 KHK4827, Placebo - Moderate to Severe Plaque Psoriasis | Phase 2 | Completed | Kyowa Kirin Co., Ltd. | 140 | 2012-12-01 | 2013-09-05 |
| Long-term Safety Study of Brodalumab in Adults With Crohn's Disease Brodalumab - Crohn's Disease | Phase 2 | Terminated | Amgen | 67 | 2011-02-02 | 2021-12-28 |
| Brodalumab (AMG 827) in Adults With Moderate to Severe Crohn's Disease Brodalumab, Placebo - Crohn's Disease | Phase 2 | Terminated | Amgen | 130 | 2010-11-09 | 2022-01-03 |
| A Study to Evaluate the Dosing of AMG 827 for Subjects With Inadequately Controlled Asthma AMG 827, Placebo - Asthma | Phase 2 | Completed | Amgen | 315 | 2010-10-04 | 2021-11-26 |
| Safety and Efficacy of AMG 827 in Subjects With RA AMG 827 - Rheumatoid Arthritis | Phase 2 | Terminated | Amgen | 211 | 2010-06-03 | 2022-02-28 |
| Study to Assess the Long-term Safety, Tolerability, and Efficacy of AMG 827 in Subjects With Psoriasis AMG 827 - Psoriasis | Phase 2 | Terminated | Bausch Health Americas, Inc. | 181 | 2010-04-01 | 2019-07-30 |
| Brodalumab (AMG 827) in Rheumatoid Arthritis (RA) Participants With Inadequate Response to Methotrexate Brodalumab, Placebo, Methotrexate - Rheumatoid Arthritis | Phase 2 | Completed | Amgen | 252 | 2009-12-30 | 2021-12-21 |
| Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 827 in Subjects With Psoriasis 70 mg SC, 210 mg SC, 140 mg SC - Psoriasis | Phase 2 | Completed | Bausch Health Americas, Inc. | 198 | 2009-12-01 | 2019-06-26 |
| Study to Evaluate the Safety, PK, PD and Efficacy of AMG 827 in Adults With Rheumatoid Arthritis Brodalumab, Placebo - Rheumatoid Arthritis | Phase 1 / Phase 2 | Completed | Amgen | 40 | 2008-10-27 | 2021-11-26 |
Arthritis, Rheumatoid (3) · Asthma (2) · Crohn Disease (2) · Psoriasis (2) · Arthritis (1) · Autoimmune Diseases (1) · Axial Spondyloarthritis (1) · Connective Tissue Diseases (1) · Hidradenitis Suppurativa (1) · Inflammation (1) · Inflammatory Bowel Diseases (1) · Irritable Bowel Syndrome (1) · Joint Diseases (1) · Musculoskeletal Diseases (1) · Non-Radiographic Axial Spondyloarthritis (1)
Amgen (8) · Bausch Health Americas, Inc. (2) · Florida Academic Dermatology Centers (1) · Kyowa Kirin Co., Ltd. (1)
United States (8) · Canada (7) · Poland (5) · Australia (4) · France (4) · Belgium (3) · Netherlands (3) · Russia (2) · South Korea (2) · Spain (2) · Austria (1) · Bulgaria (1) · Czechia (1) · Denmark (1) · Finland (1)
PMID 32207067, PMID 24286136, PMID 25313095, PMID 26547109, PMID 31493163
2014 (1)